Aditxt, Inc., was incorporated under the laws of the State of Delaware on September 28, 2017. Its mission is to enhance human well-being by redefining the way health innovations are discovered, developed and applied by transforming highly concentrated industries into socially owned and guided ecosystems. The company initially focused on an immunomodulatory technology called ADI/Adimune, which aims to prolong the life and improve the quality of life of organ transplant patients. Since then, the company has continued to expand its innovative product portfolio and subsidiaries, while continuously evaluating various promising health innovation technologies.
